Swiss TPH

Swiss TPH

Location: Basel - North West Switzerland
Discipline: Health
Affiliation: University of Basel
The Swiss Tropical and Public Health Institute (Swiss TPH), former Swiss Tropical Institute (STI), has been founded in 1943. It has research and teaching activities in the arear of international health development. In June 2009 the Institute for Social and Preventive Medicine of the University of Basel, active in the areas of environmental epidemiology and women’s health, was integrated into the Swiss TPH.
Today over 500 employees from 40 nations work worldwide for the Swiss TPH in research, teaching and services with the main goal to contribute to health development worldwide.
As an associate institute of the University of Basel, the Swiss TPH takes part in teaching within various faculties, as well as is engaged in post-graduate education and advanced training on national and international levels.
The Swiss TPH receives 81% of its income through competitive fundraising and the earnings of our service departments. The remaining budget is given by the Basel cantons and the Swiss federal government.

Excessive and unjustified use of antibiotics poses health risks and promotes antibiotic resistance. For children in lowand middle-income countries, there is a great need for action, as Julia Bielicki from the University Children's Hospital (UKBB) and Gillian Levine from the Swiss Tropical and Public Health Institute (Swiss TPH) show in a joint study. For their outstanding clinical research in pediatrics, the Basel scientists received the prestigious Pfizer Research Award 2023.
The COVID-19 pandemic has exposed weaknesses in the world's global health security networks. A global -One Health- approach is crucial for preventing, monitoring and responding to future public health emergencies. This is argued by the authors of a four paper Series published yesterday in The Lancet. Swiss TPH, with its longstanding expertise in One Health, contributed to this Series.
Julia Bohlius, Head of Education and Training at Swiss TPH, has been awarded the Dora Seif Cancer Research Prize. She receives this prize for her outstanding contributions to assessing the burden of cancer in people living with HIV, improving the quality of care for women at high risk for cervical cancer, and developing clinical guidelines for oncology interventions.
Julia Bohlius, Head of Department -Education and Training- at Swiss TPH has been awarded the Dora Seif Cancer Research Prize. She receives this prize for her outstanding contributions in assessing the burden of cancer in people living with HIV, improving the quality of care for women at high risk for cervical cancer, and developing clinical guidelines for oncology interventions.
According to a large-scale analysis of more than 32 million cardiovascular deaths over four decades, more deaths occur on very hot and very cold days. Swiss TPH contributed to this multinational study, which was published today in the journal Circulation of the American Heart Association.
The Swiss National Science Foundation (SNSF) has awarded two Starting Grants to researchers Emma Hodcroft for virology and Samuel Fuhrimann for sustainable agriculture at Swiss TPH. SNSF supports outstanding young researchers in Switzerland and enables them to lead a research project with their own team.
R. Geigy Award 2022 Goes to Three Researchers for Work on Malaria and Tuberculosis Control in Africa
Researchers Lorenz Hofer and Mgeni Tambwe are trying to stop malaria transmission in Tanzania. Astrid Knoblauch is distributing drugs to combat tuberculosis with the help of drones in Madagascar. For this, the R. Geigy Foundation awards them with the 12th R. Geigy Award 2022, endowed with CHF 20,000. In memory of the biologist and founder of the Swiss Tropical and Public Health Institute (Swiss TPH), Rudolf Geigy, the Foundation awards this prize every two years to young researchers and public health specialists who distinguish themselves through outstanding achievements in the field of poverty-related and neglected tropical diseases.
Millions of preschoolaged children affected by schistosomiasis are not receiving treatment due to the lack of a suitable medicine. To address this unmet need, the Pediatric Praziquantel Consortium has developed a potential new treatment option that has now been validated for review by the European Medicines Agency. This is a key milestone in the ongoing effort to eliminate this neglected tropical disease. As a member of the consortium, Swiss TPH conducted the clinical trials.
